PDF herunterladen
Hamostaseologie 2020; 40(04): 431-442
DOI: 10.1055/s-0040-1713735
Review Article

Navigating the Myriad of von Willebrand Factor Assays

Emmanuel J. Favaloro
1   Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead NSW, Australia
2   Sydney Centres for Thrombosis and Haemostasis, Westmead Hospital, Westmead NSW, Australia
3   School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

von Willebrand factor (VWF) represents a large and complex adhesive plasma protein whose main function is to provide a bridge between blood platelets and damaged endothelium, and thus facilitate primary hemostasis. VWF also binds to FVIII, preventing early proteolysis, and delivers this cargo to sites of vascular injury, thereby promoting clot formation and secondary hemostasis. An absence, deficiency, or defect in VWF can lead to a bleeding diathesis called von Willebrand disease (VWD), considered the most common inherited bleeding disorder. Contemporary laboratory assays used in VWD diagnosis/exclusion comprise a myriad of assays that identify the quantity (level) of VWF, as well as the multitude of VWF activities. These may use the following test abbreviations: VWF:Ag, VWF:RCo, VWF:CB, VWF:GPIbR, VWF:GPIbM, VWF:FVIIB, VWF:Ab. The current review explains what these assays are, as well as their place in VWD diagnostics.

Keywords

von Willebrand factor - VWF - von Willebrand disease - VWD - classification - diagnosis

Supplementary Material



Publikationsverlauf

Eingereicht: 01. April 2020

Angenommen: 18. Mai 2020

Artikel online veröffentlicht:
26. Juni 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Yee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Hemost 2014; 40 (01) 17-27
    PubMedGoogle Scholar
  • 2 Favaloro EJ. Diagnosis or exclusion of von Willebrand disease using laboratory testing. Methods Mol Biol 2017; 1646: 391-402
    CrossrefPubMedGoogle Scholar
  • 3 Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost 2010; 8 (01) 213-216
    CrossrefPubMedGoogle Scholar
  • 4 Sadler JE, Budde U, Eikenboom JCJ. et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
    CrossrefPubMedGoogle Scholar
  • 5 Laffan MA, Lester W, O'Donnell JS. et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (04) 453-465
    CrossrefPubMedGoogle Scholar
  • 6 Nichols WL, Hultin MB, James AH. et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (02) 171-232
    CrossrefPubMedGoogle Scholar
  • 7 Favaloro EJ, Pasalic L, Curnow J. Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology 2016; 48 (04) 303-318
    CrossrefPubMedGoogle Scholar
  • 8 Favaloro EJ, Bonar R, Marsden K. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification. Clin Lab Sci 2008; 21 (03) 178-183
    Google Scholar
  • 9 Favaloro EJ, Bonar RA, Mohammed S. et al. Type 2M von Willebrand disease - more often misidentified than correctly identified. Haemophilia 2016; 22 (03) e145-e155
    CrossrefPubMedGoogle Scholar
  • 10 Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?. Semin Thromb Hemost 2008; 34 (01) 113-127
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 11 Favaloro EJ, Mohammed S, Patzke J. Laboratory testing for von Willebrand factor antigen (VWF:Ag). Methods Mol Biol 2017; 1646: 403-416
    CrossrefPubMedGoogle Scholar
  • 12 Duncan E, Rodgers S. One-stage factor VIII assays. Methods Mol Biol 2017; 1646: 247-263
    CrossrefPubMedGoogle Scholar
  • 13 Just S. Laboratory testing for von Willebrand disease: the past, present, and future state of play for von Willebrand factor assays that measure platelet binding activity, with or without ristocetin. Semin Thromb Hemost 2017; 43 (01) 75-91
    PubMedGoogle Scholar
  • 14 Mohammed S, Favaloro EJ. Laboratory testing for von Willebrand factor ristocetin cofactor (VWF:RCo). Methods Mol Biol 2017; 1646: 435-451
    Google Scholar
  • 15 Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J. von Willebrand factor Subcommittee of the Standardization and Scientific Committee of the International Society for Thrombosis and Haemostasis. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (07) 1345-1350
    CrossrefPubMedGoogle Scholar
  • 16 Patzke J, Favaloro EJ. Laboratory testing for von Willebrand factor activity by glycoproteinIbbinding assays (VWF:GPIb). Methods Mol Biol 2017; 1646: 453-460
    Google Scholar
  • 17 Flood VH, Abshire TC, Christopherson PA. et al; Zimmerman Program Investigators. Von Willebrand disease in the United States: perspective from the Zimmerman program. Ann Blood 2018; 3: 7
    CrossrefPubMedGoogle Scholar
  • 18 Favaloro EJ, Mohammed S. Laboratory testing for von Willebrand factor collagen binding (VWF:CB). Methods Mol Biol 2017; 1646: 417-433
    Google Scholar
  • 19 Favaloro EJ, Mohammed S. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease. Thromb Res 2016; 141: 202-211
    CrossrefPubMedGoogle Scholar
  • 20 Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010; 104 (05) 1009-1021
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 21 Chen D, Tange JI, Meyers BJ, Pruthi RK, Nichols WL, Heit JA. Validation of an automated latex particle-enhanced immunoturbidimetric von Willebrand factor activity assay. J Thromb Haemost 2011; 9 (10) 1993-2002
    CrossrefPubMedGoogle Scholar
  • 22 Chandler WL, Peerschke EI, Castellone DD, Meijer P. NASCOLA Proficiency Testing Committee. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2011; 135 (06) 862-869
    CrossrefPubMedGoogle Scholar
  • 23 Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006; 32 (05) 485-491
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 24 Favaloro EJ, Oliver S, Mohammed S, Vong R. Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies. Haemophilia 2020; 26 (03) 503-512
    CrossrefPubMedGoogle Scholar
  • 25 Oliver S, Vanniasinkam T, Mohammed S, Vong R, Favaloro EJ. Semi-automated von Willebrand factor multimer assay for von Willebrand disease: Further validation, benefits and limitations. Int J Lab Hematol 2019; 41 (06) 762-771
    CrossrefPubMedGoogle Scholar
  • 26 Stufano F, Boscarino M, Bucciarelli P. et al. Evaluation of the utility of von Willebrand factor propeptide in the differential diagnosis of von Willebrand disease and acquired von Willebrand syndrome. Semin Thromb Hemost 2019; 45 (01) 36-42
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 27 Mohammed S, Favaloro EJ. Laboratory testing for von Willebrand factor: factor VIII binding (for 2N VWD). Methods Mol Biol 2017; 1646: 461-472
    Google Scholar
  • 28 Favaloro EJ, Lippi G. Recent advances in mainstream hemostasis diagnostics and coagulation testing. Semin Thromb Hemost 2019; 45 (03) 228-246
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 29 Favaloro EJ, Bonar RA, Meiring M. et al. Evaluating errors in the laboratory identification of von Willebrand disease in the real world. Thromb Res 2014; 134 (02) 393-403
    CrossrefPubMedGoogle Scholar
  • 30 Flood VH, Gill JC, Morateck PA. et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood 2011; 117 (06) e67-e74
    CrossrefPubMedGoogle Scholar
  • 31 Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007; 33 (08) 727-744
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 32 Flood VH, Gill JC, Christopherson PA. et al. Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease. J Thromb Haemost 2012; 10 (07) 1425-1432
    CrossrefPubMedGoogle Scholar
  • 33 Larsen DM, Haberichter SL, Gill JC, Shapiro AD, Flood VH. Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease. Haemophilia 2013; 19 (04) 590-594
    CrossrefPubMedGoogle Scholar
  • 34 Favaloro EJ, Henniker A, Facey D, Hertzberg M. Discrimination of von Willebrands Disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems. Thromb Haemost 2000; 84: 541-547
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 35 Favaloro EJ, Bonar R, Chapman K, Meiring M, Adcock DF. Differential sensitivity of von Willebrand factor (VWF) ‘activity’ assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. J Thromb Haemost 2012; 10 (06) 1043-1054
    CrossrefPubMedGoogle Scholar
  • 36 Favaloro EJ, Bonar R, Hollestelle MJ. et al. Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: a large international cross-laboratory study. Thromb Res 2018; 166: 96-105
    CrossrefPubMedGoogle Scholar
  • 37 Favaloro EJ. Utility of the von Willebrand factor collagen binding assay in the diagnosis of von Willebrand disease. Am J Hematol 2017; 92 (01) 114-118
    CrossrefPubMedGoogle Scholar
  • 38 Motum P, Just S, Zebeljan D. et al. A diagnosis of von Willebrand disease despite normal test results for factor VIII and von Willebrand factor antigen and activity. Am J Hematol 2019; 94 (12) 1425-1432
    CrossrefPubMedGoogle Scholar
  • 39 Zolkova J, Sokol J, Simurda T. et al. Genetic background of von Willebrand disease: history, current state, and future perspectives. Semin Thromb Hemost 2020; 46: 484-500
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 40 Cucuianu M, Pleşca L, Bodizs G, Colhon D, Brudaşcă I. Acute phase reaction and the hemostatic balance. Rom J Intern Med 1996; 34 (1–2): 13-18
    PubMedGoogle Scholar
  • 41 Curnow J, Pasalic L, Favaloro EJ. Treatment of von Willebrand disease. Semin Thromb Hemost 2016; 42 (02) 133-146
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 42 Favaloro EJ, Pasalic L, Curnow J. Monitoring therapy during treatment of von Willebrand disease. Semin Thromb Hemost 2017; 43 (03) 338-354
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 43 Frontroth JP, Favaloro EJ. Ristocetin-induced platelet aggregation (RIPA) and RIPA mixing studies. Methods Mol Biol 2017; 1646: 473-494
    Google Scholar
  • 44 Favaloro EJ, Pasalic L, Curnow J. Type 2M and type 2A von Willebrand disease: similar but different. Semin Thromb Hemost 2016; 42 (05) 483-497
    Artikel in Thieme ConnectPubMedGoogle Scholar